Business Wire

Sigfox France Demonstrates the 0G Potential in Response to the Scheduled Shutdown of the Public Switched Telephone Network (PSTN)

14.5.2019 14:35:00 EEST | Business Wire | Press release

Share

Within three years, all switched networks will have disappeared and most of them will be replaced by exchanges based on the IP protocol, with or without wires. This standardization of exchanges allows substantial gains in telecommunications infrastructures, but it generates significant costs for migrating from existing solutions based on switched networks. A lot of equipment will have to be adapted or replaced without creating added value or new services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005512/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The MutaKom box (Photo: Sigfox)

In order to meet this major challenge, which will impact millions of devices, Sigfox, the world's leading IoT service provider and first global 0G network operator, and J2C, a specialist in service offerings in the security market, have developed the MutaKom box, which replaces the previous wiring that linked the devices to the PSTN. The MutaKom solution offers immediate service continuity and is economically unbeatable.

The PSTN still satisfies multiple uses including: telemetry, remote reading, remote monitoring of premises, remote maintenance or remote alarms of machines, gauges, industrial automatons and alarm centres. All these equipments amount to a fleet of several million units, in France only, which will quickly need to find a simple, immediate and inexpensive alternative link.

The market for alarm control units in France only is estimated at 1.2 million (GPMSE and ADMS sources). The stakes around the termination of the PSTN are therefore crucial. With MutaKom providing an optional backup battery, alarm centres will maintain a similar energy autonomy, while increasing security against hacking or sabotage attempts. Indeed, the wireless link provided by the Sigfox 0G network is resistant to all types of jammers, and makes it impossible to cut the telephone cable to isolate the alarm from the remote monitor.

As Patrick Cason, Managing Director at Sigfox France, points out: "We are targeting a large market in Europe with millions of alarm centres and other technical equipment for which the only solution, before the arrival of the MutaKom offer, was to migrate to more expensive equipment without real added value. With this in mind, MutaKom is, in our opinion, the most competitive offer on the market”.

Christophe Sautter, Executive President of the GIP Group (Générale Industrielle de Protection), first security player in France to test the MutaKom solution: "The first tests were more than convincing. We believe that the simplicity of implementation and cost savings will be significant with a tangible impact on customer satisfaction”.

This Sigfox network application illustrates once again the potential of the 0G network to permanently or temporarily compensate for the unavailability of existing networks. The 0G standard is there to provide a minimal and functional link to serve the successive changes in telecommunications networks, which tend to become more complex in order to deliver ever more speed, while usage remains simple.

More information on MutaKom offer: www.mutakom.fr

About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.

Today, the network is available in 60 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France, and also has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.

About J2C
J2C is a new French player, based in Montpellier, created by specialists in the security and telecommunications market, whose mission is to propose new service offers on the security market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye